SpectraWAVE Announces $50M Series B Financing to Drive Commercial Expansion and Product Additions to the HyperVue™ Imaging System
Pulse Biosciences, Inc. Appoints Paul LaViolette to Its Board of Directors - Paul LaViolette to serve as Co-Chairman alongside Robert W. Duggan, adding 40 years of medical technology development, operating and leadership expertise
Spineology® Announces $25 Million Equity Financing – Funding to aid in acceleration of commercial growth, clinical education programs, and product development enhancements for highly-differentiated OptiMesh® implant portfolio –
Edwards Lifesciences Expands Structural Heart Portfolio With Acquisitions of JenaValve and Endotronix
Endotronix Receives FDA Premarket Approval of the Cordella™ PA Sensor System for the Treatment of Heart Failure
Merck signs $3bn deal for Kate Bingham-backed eye disease biotechRead More
SV Health Investors-created EyeBio to be acquired by MSD for up to $3 billion
Nanopath Receives $4 Million in Grants from National Institutes of Health and National Science Foundation
QurAlis to Present Data That Show its Splice-Switching ASOs Restore UNC13A Function in ALS and Frontotemporal Dementia
SV investment has resulted in the approval of 24 novel therapeutics
SV Health Investors bolsters senior biotech team - appoints Nikola Trbovic as Managing Partner and hires Jamil Beg as Partner
Hightop Health adds industry veteran to Board of Directors - Seasoned CEO and McLean Hospital Board Chair joins Hightop’s executive leadership
Merck to Acquire Caraway Therapeutics, Inc.
EyeBio Announces Expansion of Series A to $130 Million, Advances Development of Restoret for Retinal Diseases
SV Health Investors partners with HIT Executives Dave Dyell and Marc Hirshfield to Lead Recapitalization of Innovative Consulting Group
SV News
- 8 October 2019Portfolio NewsAVROBIO Announces First Patient Dosed in Phase 1/2 Trial of Gene Therapy for Cystinosis
- 1 October 2019Portfolio NewsEndotronix Closes Expanded Series D Financing Round of $70 Million for Heart Failure Solution
- 30 September 2019Portfolio NewsDDF notes Ribometrix strategic collaboration with Vertex Pharmaceuticals to discover and develop RNA-targeted small molecule therapeutics
- 27 September 2019Portfolio NewsMisonix, Inc. Completes Acquisition of Regenerative Medical Company Solsys Medical
- 27 September 2019Portfolio NewsDDF notes Ribometrix raises $7.8 Million in New Funding to Advance RNA-Targeting Drug Discovery Platform with Investment from DDF
- 24 September 2019Portfolio NewsArtios Pharma Appoints Tania Dimitrova as Chief Business Officer and Expands Presence in the United States
- 9 September 2019SV NewsDDF notes the appointment of Christian Jung, PhD as Partner
- 27 August 2019Portfolio NewsPIONYR Immunotherapeutics Announces Key Leadership Team Addition and Clinical Candidates Targeting Tumor-Associated Macrophages
- 13 August 2019Portfolio NewsDeciphera Pharmaceuticals Announces Positive Top-line Results from INVICTUS Pivotal Phase 3 Clinical Study of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumors
- 12 August 2019Portfolio NewsDDF notes AstronauTx secures £6.5 million Financing with Investment from DDF
- 8 August 2019Portfolio NewsLilly, Evidation Health and Apple Study Shows Personal Digital Devices May Help in the Identification of Mild Cognitive Impairment and Mild Alzheimer’s Disease Dementia
- 7 August 2019Portfolio NewsQ&A with Pulmocide CEO Garth Rapeport – Why Pulmocide is developing targeted lung therapy.